Notably, ACC express high transcript levels of the proapoptotic BAX and low levels of BCL2 (Supplementary Fig. S5B), suggesting that inhibition of BCL2 could shift the proapoptotic balance in ACC treated with Venetoclax. Here, BAX is linked to adrenal cortex carcinoma.